Search

238 Result(s)
Sort by

Our Innovation Strategy

Our Innovation Strategy

Our discovery research strategy is designed to sustain our track record of innovation and look for new and breakthrough medicines.
Introducing Karl and Klara Kidney

Introducing Karl and Klara Kidney

Kidney disease and type 2 diabetes are closely linked, and share many of the same risk factors and pathological pathways
NeO - smart and sustainable vaccines

NeO - smart and sustainable vaccines

The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Open Innovation at Boehringer Ingelheim

Open Innovation at Boehringer Ingelheim

Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
More Health Overview

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Pulmonary Fibrosis Awareness Month 2020

Pulmonary Fibrosis Awareness Month 2020

Hear what Peter Fang said about pulmonary fibrosis awareness month, our commitment to advancing care and our engaging new campaign, ‘the most important postcard you will ever write’
Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
Fighting against rabies in Nepal

Fighting against rabies in Nepal

Read about a pilot project of a critical importance which aims to raise awareness and knowledge of rabies in Nepal.